유럽 연합 - 몰타어 - EMA (European Medicines Agency)

zoetis belgium s.a. - canine parainfluenza virus, leptospira and rabies virus. - immunoloġiċi għall-canidae, jgħixu u virali inattivati u l-vaċċini batterjali - klieb - tilqim attiv ta 'klieb ta' sitt ġimgħat għall-prevenzjoni tal-sinjali kliniċi u l-eskrezzjoni virali-kawża mill-klieb parainfluenza tal-virus, li jipprevjenu l-sinjali kliniċi, l-infezzjoni u l-eskrezzjoni fl-awrina jikkawżaw mill leptospira serovars bratislava, canicola, grippotyphosa u icterohaemorrhagiae u biex jimpedixxi l-mortalità, sinjali kliniċi u jikkawżaw l-infezzjoni mill-virus tar-rabbja.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - majloma multipla - aġenti antineoplastiċi - empliciti huwa indikat, flimkien ma 'lenalidomide u dexamethasone għall-kura ta' majeloma multipla f'pazjenti adulti li jkunu rċevew mill-anqas terapija waħda qabel (ara sezzjonijiet 4. 2 u 5.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

astrazeneca ab - olaparib - neoplażmi fl-ovarji - aġenti antineoplastiċi - ta 'l-ovarji cancerlynparza huwa indikat bħala monoterapija għall -: l-manteniment tat-trattament ta' pazjenti adulti b'avvanzat (medjevali stadji iii u iv) brca1/2 mutat (linja ġerminali u/jew somatiċi) ta 'grad għoli ta' l-epitilju ta 'l-ovarji, tubu fallopjan jew primarja peritoneali-kanċer li huma fir-rispons (sħiħa jew parzjali) wara t-tlestija ta' l-ewwel linja bbażata fuq il-platinu ' kimoterapija. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 u 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. il-pazjenti għandu jkollhom qabel kienu kkurati bil-anthracycline u taxane fil - (neo)adjuvant jew metastatiku-istabbiliment sakemm il-pazjenti li ma kienux tajbin għal dawn it-trattamenti (ara sezzjoni 5. pazjenti bl-ormon tat-riċettur (hr)-kanċer tas-sider posittiv għandu wkoll għamlu progress fuq jew wara qabel l-terapija endokrinali, jew jiġu kkunsidrati bħala mhux adattati għal terapija endokrinali. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanoma - aġenti antineoplastiċi - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 u 5. kura awżiljarja tal-melanomadabrafenib flimkien ma trametinib huwa indikat għall-kura awżiljarja ta ' pazjenti adulti b'fażi iii melanoma bil-braf v600, wara li jitlesta r-risezzjoni. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrite, rewmatika - immunosoppressanti - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 u 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

grünenthal gmbh - lesinurad - iperurċemija - preparazzjonijiet antigout - zurampic, f ' għaqda mal-inibitur oxidase xanthine, huwa indikat fl-adulti għall-trattament adjunctive ta ' hyperuricaemia fil-pazjenti gout (bi jew mingħajr tophi) li ma kisbux mira tas-serum uric acid livelli b ' doża xierqa ta ' l-oxidase ta ' xanthine inibitur waħdu.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

novartis europharm limited - ribociclib succinate - neoplażmi tas-sider - aġenti antineoplastiċi - kisqali huwa indikat għall-kura ta 'nisa bl-ormon tat-riċettur (hr)‑pożittivi, tal-bniedem tar-riċettur tal-fattur tat-tkabbir epidermali 2 (her2) negattivi lokalment avvanzata jew metastatika tal-kanċer tas-sider f'kumbinazzjoni ma' inibitur aromatase jew fulvestrant bħala inizjali endokrinali bbażata fuq it-terapija, jew f'nisa li kienu rċevew qabel terapija endokrinali. fil‑ pre- jew perimenopausal-nisa, l-endokrinali it-terapija għandha tingħata flimkien ma 'ormon ta' lutejniżżazzjoni‑releasing hormone (lhrh) agonist.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - sera immuni u immunoglobulini, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. ara t-taqsimiet 4. 4 u 5.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - afatinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - giotrif bħala monoterapija hija indikata għat-trattament ofepidermal growth factor receptor (egfr) tki pazjenti adulti naΐve għal kura bil-lokalment avvanzat jew dak metastatiku li mhux ta 'ċelluli żgħar kanċer tal-pulmun (nsclc) ma' l-attivazzjoni tal-egfr-mutazzjoni tal - (s);lokalment avvanzat jew metastatiku nsclc tal-kanser skwamuż tar-istoloġija tal-progress fuq jew wara ibbażat fuq il-platinu ' kimoterapija.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - immunosoppressanti - jekk jogħġbok irreferi għad-dokument ta 'informazzjoni dwar il-prodott.